-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将BLDR的12个月目标价从125美元下调至85美元,基于2027年13.1倍的市盈率,该倍数高于该股10年平均预期市盈率12.1倍,但考虑到市场周期性低谷,这一调整是合理的。我们将2026年调整后每股收益预期从6.69美元下调至4.10美元,并将2027年调整后每股收益预期从8.01美元下调至6.50美元。BLDR公布的2026年第一季度调整后每股收益为0.27美元,低于市场预期的1.51美元(同比下降82%),也远低于市场普遍预期的0.37美元。 BLDR第一季度销售额下降11%至32.9亿美元(比市场预期高出1.3亿美元),但毛利率下降220个基点至28.3%。BLDR表示,目前预计2026年净销售额为146亿至156亿美元,调整后EBITDA为11亿至15亿美元,而此前的预期分别为148亿至158亿美元和13亿至17亿美元。管理层表示,公司将继续专注于自身可控因素,包括服务客户、拓展差异化增值解决方案组合以及利用技术加速增长并提升运营效率。我们认为,BLDR第一季度的业绩凸显了该公司在疲软的房地产市场中所面临的挑战。
Related Articles
Star Sports Medicine Soars 192% in Hong Kong Trading Debut
Star Sports Medicine's (HKG:1609) shares opened 192.4% above their initial public offering price in a stellar Hong Kong debut Tuesday morning.The China-based medical device company opened at HK$288 per share, well above the offer price of HK$98.50.
Impact Therapeutics Launches Up to HK$913 Million Hong Kong IPO
Impact Therapeutics (HKG:7630) launched its Hong Kong initial public offering on Tuesday, seeking to raise up to about HK$913 million from the deal.The China-based biotechnology company is offering 42 million shares at an indicative maximum price of HK$21.75 per share, according to a Hong Kong bourse filing.The offering comprises 4.2 million shares for Hong Kong investors and 37.8 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by May 11, with allocation results due by May 12, ahead of the company's planned trading debut on May 13.Net proceeds will be used mainly to fund the clinical development, regulatory approval, and commercialization of its core product, senaparib, as well as support the development of key pipeline products.The funds will also be used for research and development of other pipeline assets, expansion of R&D platforms, and for working capital and general corporate purposes.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are acting as joint sponsors.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers.CMB International Capital is acting as a joint global coordinator and joint lead manager, while Tiger Brokers (HK) Global is acting as a joint bookrunner and joint lead manager.
Market Chatter: SK Hynix Shares Gain 13% After US Tech Giants Signal No Slowdown in AI Spending
Shares of SK Hynix (KRX:000660) closed nearly 13% higher on Monday, ending trading at a new high of 1,447,000 won per share, after all four of the US tech giants indicated that spending on AI will not slow down, Reuters said in a same-day report.Total AI spending is estimated to surpass $700 billion in 2026, up from about $600 billion previously, as Microsoft and Meta announced larger-than-expected capital expenditure plans, which were partly led by higher memory chip prices, while maintaining confidence in their investments, the report said.In addition, Bank of Korea Senior Deputy Governor Ryoo Sang-dai said that the current chip market boom is likely to last longer as compared to past cycles, echoing similar outlooks from Samsung Electronics (KRX:005930) and SK Hynix during their earnings calls in April, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)